Scholarlink

Introduction <p>Established (Ki-67, H3K27Me3) protein biomarkers correlate to clinically aggressive meningioma and can be quickly and easily assessed by immunohistochemistry (IHC). Novel (S100B, SCGN, ACADL, MCM2) markers have also been proposed. The aim of this study was to determine if IHC-based biomarker expression is correlated with volumetric growth rates in recurrent intracranial meningioma following primary resection.</p> Methods <p>This was a single-centre retrospective cohort study of adults (≥ 18 years) with surgical resection of recurrent meningioma. Serial tumour volumes were calculated on serial MRI using the ellipsoid formula. Growth rates were calculated and adjusted for time since resection. IHC was performed on paired samples from first and second resections for six markers. Associations between marker expression and tumour growth trajectories were tested using Kruskal–Wallis and linear mixed-effects models.</p> Results <p>Thirty-one patients were included (mean age 53.1 years, 71% female). No significant cohort differences were found in IHC expression between primary and recurrent samples (all McNemar <i>P</i> &gt; 0.1). Tumours were positive for ≥ 2 novel markers in 17.2% of primary and 34.5% of recurrent samples. Neither established (Ki-67, H3K27Me3) nor novel markers predicted absolute or relative growth rates (all Kruskal–Wallis <i>P</i> &gt; 0.2). Linear mixed-effects models confirmed no association between marker expression and longitudinal tumour volume trajectories (all <i>P</i> ≥ 0.1).</p> Conclusion <p>IHC expression of established or novel markers did not correlate with meningioma volumetric growth. IHC-based stratification is limited by overlapping expression patterns and inconsistent categorisation and is not recommended for routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunohistochemistry markers of molecular subtype do not correlate with the growth behaviour for recurrent meningiomas – a cohort study

  • 期刊论文

  • 发表日期：

    2025年11月21日

查看全文
  • George E. Richardson,
  • Mohammad A. Mustafa,
  • Abigail L. Clynch,
  • Abdurrahman I. Islim,
  • Samantha J. Mills,
  • Nitika Rathi,
  • Rasheed Zakaria,
  • Emanuele Ricci,
  • Lorenzo Ressel,
  • Michael D. Jenkinson

摘要

Introduction

Established (Ki-67, H3K27Me3) protein biomarkers correlate to clinically aggressive meningioma and can be quickly and easily assessed by immunohistochemistry (IHC). Novel (S100B, SCGN, ACADL, MCM2) markers have also been proposed. The aim of this study was to determine if IHC-based biomarker expression is correlated with volumetric growth rates in recurrent intracranial meningioma following primary resection.

Methods

This was a single-centre retrospective cohort study of adults (≥ 18 years) with surgical resection of recurrent meningioma. Serial tumour volumes were calculated on serial MRI using the ellipsoid formula. Growth rates were calculated and adjusted for time since resection. IHC was performed on paired samples from first and second resections for six markers. Associations between marker expression and tumour growth trajectories were tested using Kruskal–Wallis and linear mixed-effects models.

Results

Thirty-one patients were included (mean age 53.1 years, 71% female). No significant cohort differences were found in IHC expression between primary and recurrent samples (all McNemar P > 0.1). Tumours were positive for ≥ 2 novel markers in 17.2% of primary and 34.5% of recurrent samples. Neither established (Ki-67, H3K27Me3) nor novel markers predicted absolute or relative growth rates (all Kruskal–Wallis P > 0.2). Linear mixed-effects models confirmed no association between marker expression and longitudinal tumour volume trajectories (all P ≥ 0.1).

Conclusion

IHC expression of established or novel markers did not correlate with meningioma volumetric growth. IHC-based stratification is limited by overlapping expression patterns and inconsistent categorisation and is not recommended for routine clinical practice.